| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ustekinumab |
| Brand | Stelara® |
| Indication | For the treatment of moderate to severe psoriasis. |
| Assessment Process | |
| Full submission received from Applicant | 01/07/2009 |
| NCPE assessment completed | 01/11/2009 |
| NCPE assessment outcome | Reimbursement recommended. |
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.